These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
425 related articles for article (PubMed ID: 29543644)
1. Intrathecal Drug Delivery Systems for Refractory Pancreatic Cancer Pain: Observational Follow-up Study Over an 11-Year Period in a Comprehensive Cancer Center. Carvajal G; Dupoiron D; Seegers V; Lebrec N; Boré F; Dubois PY; Leblanc D; Delorme T; Jubier-Hamon S Anesth Analg; 2018 Jun; 126(6):2038-2046. PubMed ID: 29543644 [TBL] [Abstract][Full Text] [Related]
2. Intrathecal cervical analgesia for cancer pain: a 12-year follow-up study in a comprehensive cancer center. Dupoiron D; Bienfait F; Carvajal G; Seegers V; Douillard T; Jubier-Hamon S; Delorme T; Julienne A; Pluchon YM; Ribault N; Nader E; Lebrec N Reg Anesth Pain Med; 2024 Oct; 49(10):757-763. PubMed ID: 37973378 [TBL] [Abstract][Full Text] [Related]
3. Intrathecal Drug Delivery Systems for Cancer Pain: An Analysis of a Prospective, Multicenter Product Surveillance Registry. Stearns LM; Abd-Elsayed A; Perruchoud C; Spencer R; Hammond K; Stromberg K; Weaver T Anesth Analg; 2020 Feb; 130(2):289-297. PubMed ID: 31567325 [TBL] [Abstract][Full Text] [Related]
4. Optimizing Initial Intrathecal Drug Ratio for Refractory Cancer-Related Pain for Early Pain Relief. A Retrospective Monocentric Study. Dupoiron D; Leblanc D; Demelliez-Merceron S; Bore F; Seegers V; Dubois PY; Pechard M; Robard S; Delorme T; Jubier-Hamon S; Carvajal G; Lebrec N Pain Med; 2019 Oct; 20(10):2033-2042. PubMed ID: 31329956 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of intrathecal drug delivery system for intractable pain in advanced malignancies: A prospective cohort study. Zheng S; He L; Yang X; Li X; Yang Z Medicine (Baltimore); 2017 Mar; 96(11):e6354. PubMed ID: 28296770 [TBL] [Abstract][Full Text] [Related]
6. Retrospective Analysis of Intrathecal Drug Delivery: Outcomes, Efficacy, and Risk for Cancer-Related Pain at a High Volume Academic Medical Center. Sayed D; Monroe F; Orr WN; Phadnis M; Khan TW; Braun E; Manion S; Nicol A Neuromodulation; 2018 Oct; 21(7):660-663. PubMed ID: 29446171 [TBL] [Abstract][Full Text] [Related]
7. Pancreatic Cancer Related Pain: Review of Pathophysiology and Intrathecal Drug Delivery Systems for Pain Management. Carvajal G Pain Physician; 2021 Aug; 24(5):E583-E594. PubMed ID: 34323445 [TBL] [Abstract][Full Text] [Related]
8. Clinical observation of the treatment of refractory cancer pain with cancer pain information platform and IDDS under home analgesia mode: A retrospective study. Ding Y; Deng H; Peng J Medicine (Baltimore); 2024 Jul; 103(27):e38765. PubMed ID: 38968525 [TBL] [Abstract][Full Text] [Related]
9. Initiation of Intrathecal Drug Delivery Dramatically Reduces Systemic Opioid Use in Patients With Advanced Cancer. Sindt JE; Odell DW; Dalley AP; Brogan SE Neuromodulation; 2020 Oct; 23(7):978-983. PubMed ID: 32459393 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of intrathecal drug delivery system for refractory cancer pain patients: a single tertiary medical center experience. Lin CP; Lin WY; Lin FS; Lee YS; Jeng CS; Sun WZ J Formos Med Assoc; 2012 May; 111(5):253-7. PubMed ID: 22656395 [TBL] [Abstract][Full Text] [Related]
11. Long-Term Intrathecal Analgesia With a Wireless Analgesia Pump System in the Home Care of Patients With Advanced Cancer. Liu HJ; Li WY; Chen HF; Cheng ZQ; Jin Y Am J Hosp Palliat Care; 2017 Mar; 34(2):148-153. PubMed ID: 26537661 [TBL] [Abstract][Full Text] [Related]
12. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Smith TJ; Coyne PJ; Staats PS; Deer T; Stearns LJ; Rauck RL; Boortz-Marx RL; Buchser E; Català E; Bryce DA; Cousins M; Pool GE Ann Oncol; 2005 May; 16(5):825-33. PubMed ID: 15817596 [TBL] [Abstract][Full Text] [Related]
14. Intrathecal Drug Delivery Systems for Cancer Pain Control: Insights on Current Contemporary Practices in the US. Goel V; Kumar V; Blaes A; Gulati A Neuromodulation; 2023 Aug; 26(6):1256-1262. PubMed ID: 37318432 [TBL] [Abstract][Full Text] [Related]
15. Intrathecal morphine delivered via subcutaneous pump for intractable pain in pancreatic cancer. Gilmer-Hill HS; Boggan JE; Smith KA; Frey CF; Wagner FC; Hein LJ Surg Neurol; 1999 Jan; 51(1):6-11. PubMed ID: 9952116 [TBL] [Abstract][Full Text] [Related]
16. Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients. Smith TJ; Coyne PJ J Palliat Med; 2005 Aug; 8(4):736-42. PubMed ID: 16128647 [TBL] [Abstract][Full Text] [Related]
17. Spinal analgesia for severe cancer pain: A retrospective analysis of 60 patients. Kiehelä L; Hamunen K; Heiskanen T Scand J Pain; 2017 Jul; 16():140-145. PubMed ID: 28850391 [TBL] [Abstract][Full Text] [Related]
19. Intrathecal Drug Delivery Systems for Cancer Pain: A Health Technology Assessment. Ontario Health Ont Health Technol Assess Ser; 2024; 24(2):1-162. PubMed ID: 38344326 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Intrathecal Drug Delivery Systems for the Management of Cancer Pain: A Systematic Review and Meta-Analysis. Duarte R; Copley S; Nevitt S; Maden M; Al-Ali AM; Dupoiron D; Eldabe S Neuromodulation; 2023 Aug; 26(6):1126-1141. PubMed ID: 35422368 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]